Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene

Advances in Experimental Medicine and Biology

Volumn 451, Issue , 1998, Pages 107-113

  Searle, P F ^a   Weedon, S J ^a   McNeish, I A ^a   Gilligan, M G ^a   Ford, M J ^b   Friedlos, F ^c   Springer, C J ^c   Young, L S ^a   Kerr, D J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; BACTERIAL ENZYME; CISPLATIN; FLUCYTOSINE; GANCICLOVIR; NITROREDUCTASE; PRODRUG; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; BACTERIAL GENE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG SENSITIZATION; ESCHERICHIA COLI; GENE TRANSFER; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; RETROVIRUS; TUMOR CELL DESTRUCTION;

EID: 0031724854     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5357-1_17     Document Type: Article

References (11)

1. R. J. Knox, et al., 1992: The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954). II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorasc. Biochem. Pharmacol. 44, 2297-2301
2. R. J. Knox. et al., 1988: A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol. 37, 4661-4669
3. G. M. Anlezark, et al., 1992: The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) - I. Purification and properties of a nitroreductase enzyme from Escherichia coli- a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 44, 2289-2295
4. R. J. Knox. et al., I993: Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954. Biochem. Pharmacol. 46, 797-803
5. J. A. Bridgewater, et al., 1995: Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A, 2362-2370
6. N. K. Green, et al., 1997: Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Therapy 4, 229-238
7. D. Markowitz, S. Goff and A. Bank, 1988: Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167, 400-406
8. F.-L. Cosset, et al., 1995: High-liter packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69, 7430-7436
9. N. E. Bowles, et al., 1996: A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo. Human Gene Therapy 7, 1735-1742
10. G. W. G. Wilkinson and A. Akrigg, 1992: Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res. 20, 2233-2239
11. E. Frei, et al., 1988: Preclinical studies and correlation of the effects of alkylating dose. Cancer Res. 48, 6417-6423